Trials / Completed
CompletedNCT00807677
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Millennium Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of TAK-901 in subjects with advanced hematological malignancies, and to further assess the safety and tolerability of TAK-901 at or below the MTD in an expanded cohort of subjects in order to select a dose for future studies.
Conditions
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Chronic Myelogenous Leukemia
- Chronic Lymphocytic Leukemia
- Multiple Myeloma
- Waldenstrom's Macroglobulinemia
- Myelodysplastic Syndrome
- Philadelphia Chromosome-negative CML
- Myeloid Metaplasia
- Myelofibrosis
- Advanced Polycythemia
- Non-Hodgkins Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAK-901 | TAK-901 will be administered via IV infusion over a 3-hour period on Days 1,4,8,11,15,18,22, and 25 of each 28-day cycle. |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2012-09-01
- Completion
- 2013-03-01
- First posted
- 2008-12-12
- Last updated
- 2013-07-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00807677. Inclusion in this directory is not an endorsement.